Sun Pharma Buys US, Hungarian Drug Plants from Valeant
Sun Pharma Buys US, Hungarian Drug Plants from Valeant
Sun Pharma (Mumbai, India) has purchased two manufacturing plants from Valeant Pharmaceuticals (Costa Mesa, CA) for undisclosed sums.
On Wednesday, Sun announced it had agreed to buy Valeant's Bryan, Ohio, liquid and semisolid dosage facility. Last month, Valeant sold Sun Pharma a raw-materials and dosage-form manufacturing operation in Hungary.
Valeant is a $680-million specialty pharma company focusing on neurology, dermatology, and infectious disease. The sales, says CEO Timothy C. Tyson, are part of the company's plan to consolidate manufacturing into four facilities by the end of 2006.
Sun Pharma is the 5th-ranked Indian pharmaceutical company, specializing in psychiatry, neurology, cardiology, diabetes, gastroenterology, and orthopedics. Sun bought the plants to expand its generics business on two continents. The Ohio acquisition, said Chairman Dilip Shanghvi, will join Sun's US subsidiary, Caraco Pharmaceutical Laboratories (Detroit, MI), to strengthen Sun's American generics business and give the company capacity in liquid, cream, and ointment formulations. The Hungarian purchase expands capacity in bulk actives and product development, and will speed up product roll-out in Europe.
–Douglas McCormick
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
